The Apex Times
Above the Noise
Business Wire
BusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex Times
Back to front
Moderna wins U.S. FDA approval for influenza vaccine mFLUSIVA, expanding its shot portfolio
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 5, 10:29 PM EDT

Moderna wins U.S. FDA approval for influenza vaccine mFLUSIVA, expanding its shot portfolio

The approval gives Moderna a new FDA-authorized product for seasonal flu, adding to a growing list of globally approved vaccines as the company looks to broaden its addressable market beyond COVID-19.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna said the U.S. Food and Drug Administration has approved its influenza vaccine mFLUSIVA, positioning the company to add a new non-COVID product to its portfolio at a time when investors and health systems are seeking broader vaccine pipelines.

In a post carried by Yahoo Finance, Moderna described mFLUSIVA as its fifth approved product globally and the fourth product that has received FDA approval. The company also said it expects initial supply to be available in select retailers within the coming weeks.

The approval matters for Moderna because influenza vaccines, unlike pandemic-focused programs, are recurring, seasonal products. That makes them strategically relevant for companies that want to diversify revenue streams tied to specific public health campaigns.

Moderna’s mFLUSIVA is an mRNA-based influenza vaccine. In plain terms, mRNA vaccines use a genetic instruction delivered to the body that prompts cells to produce a target protein, helping the immune system recognize and respond to the virus later. For Moderna, the technology platform is the through-line, while each approval adds to how many product categories it can serve.

The FDA action also continues the broader industry push toward next-generation and platform-based influenza vaccines. While the seasonal flu market is already served by multiple vaccine makers, new approvals can affect purchasing decisions, formularies, and competition around price, availability, and patient uptake.

Still, details released in the Yahoo Finance report were limited. Moderna did not provide, in the information available here, dosing specifics, composition details for the formulation, label language on age groups or indications, or comparative efficacy and safety outcomes in the post.

For buyers and clinicians, the practical question in the near term is availability and labeling. Moderna’s statement that select retailers will carry supply in the coming weeks suggests commercialization is beginning, but the timing, distribution footprint, and exact point of sale channels were not spelled out in the report.

Looking ahead, investors and the market will likely focus on whether Moderna can translate the approval into sustained demand, how quickly distribution expands beyond select retailers, and what the company discloses next about guidance, manufacturing readiness, and commercial traction for mFLUSIVA.

Why It Matters

  • A new FDA-authorized seasonal flu product could diversify Moderna’s vaccine revenue profile beyond COVID-19.
  • Influenza is a recurring market, which can matter for companies seeking more stable demand versus one-off public health programs.
  • The approval adds to competitive pressure in seasonal flu procurement, especially around next-generation vaccine platforms.
  • Near-term market reaction will likely hinge on commercialization details not yet provided, including distribution breadth and how quickly supply scales.

Sources

Key Facts

  • Moderna said the U.S. FDA approved its influenza vaccine mFLUSIVA.
  • Moderna described mFLUSIVA as its fifth approved product globally.
  • Moderna said mFLUSIVA is its fourth product approved by the FDA.
  • Moderna expects early mFLUSIVA supply to be available in select retailers within the coming weeks.

Healthcare Related

Moderna wins U.S. FDA approval for influenza vaccine mFLUSIVA, expanding its shot portfolio | The Apex Times